No clinically significant pharmacokinetic interactions were observed when valsartan was coadministered
with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. The
valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate
more than atenolol alone.
Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the
time-course of the anticoagulant properties of warfarin.
CYP 450 Interactions: The enzyme(s) responsible for valsartan metabolism have not been
identified but do not seem to be CYP 450 isozymes. The inhibitory or induction potential of valsartan on CYP 450 is
As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing
diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing
potassium may lead to increases in serum potassium and in heart failure patients to increases in serum